The current coronavirus disease 2019 (COVID-19) pandemic induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused a global increase in hospitalizations and deaths. Unfortunately, effective medicines to fight this disease, especially in the severely ill patients, are still lacking \[[@CR1]\]. Tocilizumab, a humanized monoclonal antibody used in rheumatoid arthritis treatment, might also be effective in treating severe COVID-19 as it could selectively target the interleukin-6 (IL-6) receptor \[[@CR2]\]. Considering the uncertain efficacy of tocilizumab treatment in severe COVID-19, we conducted a systematic review and meta-analysis to clarify this added effect of tocilizumab.

We performed a systematic search of PubMed, Embase, Medline, Cochrane, and CNKI database through 25 July 2020, using the following search terms alone or in combination: (1) "COVID-19," (2) "coronavirus," (3) "SARS-CoV-2," (4) "COVID," (5) "anti-interleukin-6 receptor antibodies," (6) "anti-IL-6 receptor antibodies," (7) "anti-IL-6," (8) "tocilizumab," (9)"sarilumab," and (10) "siltuximab." Clinical trials regarding tocilizumab as a therapeutic intervention were selected. Two independent investigators selected eligible trials and extracted data from articles. Discrepancies in screening/data extraction were addressed by group discussion. Proportional variables were measured by odds ratio (OR) and corresponding 95% confidence intervals (CI). *P* values \< 0.05 were considered statistically significant. Significant heterogeneity (*P* \< 0.10 or *I*^2^ ≥ 50%) was evaluated by chi-square and *I*^2^ tests in a fixed-effect model. The comparison of the outcome between tocilizumab and control was conducted by using Review Manager 5.4 (Revman, The Cochrane Collaboration, Oxford, UK).

Finally, 10 studies involving 1675 severe COVID-19 patients were included, among which only one trial was a randomized controlled trial, while the rest were all retrospective cohort studies. These studies included COVID-19 patients who were older/elderly (mean/median age ≥ 52 years) in America, Europe, and India, among whom 675 patients received tocilizumab, while 1000 patients underwent standard care. Severe COVID-19 patients received tocilizumab via intravenous or subcutaneous formulation, while doses and administration time points varied. Standard care included hydroxychloroquine, lopinavir/ritonavir, remdesivir, azithromycin, low weight heparin, and/or methylprednisolone, among others **(**Table [1](#Tab1){ref-type="table"}**)**. Our meta-analysis result revealed a significant difference in mortality between tocilizumab group (132/675, 19.5%) and control group (283/1000, 28.3%) in the fixed-effect model (OR, 0.47; 95%Cl, 0.36--0.60; *P* \< 0.00001), suggesting efficacy of tocilizumab treatment for severe COVID-19. However, high heterogeneity was also observed (*I*^2^ = 74%, *P* \< 0.0001) as shown in Fig. [1](#Fig1){ref-type="fig"}. SARS-CoV-2 infection might cause a hyperimmune response associated with acute respiratory distress (ARDS), the latteris a leading cause of death for severe COVID-19 \[[@CR3]\]. Uncontrolled immune activation would result in cytokine storm, also known as cytokine release syndrome (CRS), appearing as overproduction of pro-inflammatory cytokines and chemokines \[[@CR4]\]. Severe COVID-19 patients always present elevated inflammatory markers, among which the elevation of IL-6 is associated with severity of COVID-19 \[[@CR5]\]. Besides, the upregulated expression of IL-6 receptor (IL-6R) was also detected in COVID-19 patients \[[@CR6]\]. Therefore, IL-6/IL6R might serve as a messenger not only for transmitting inflammatory signals throughout the lung and other organs but also by activating cellular signal pathway, thus causing ARDS and multiple organ dysfunction. It is reasonable to speculate that IL-6 blockade is beneficial for avoiding poor prognosis. Table 1Study characteristics and demographics of included severely ill coronavirus disease 2019 (COVID-19) patientsArticleStudy designCountryTotal patientsMean/median age (years)Standard careTocilizumab treatmentPatients categoryPrimary outcomesCampochiaro CEur J Intern Med 2020Single-center retrospective cohort studyItaly6560 (control)64 (tocilizumab)Hydroxychloroquine, lopinavir/ritonavir, ceftriaxone, azithromycinFirst intravenous 400 mg, second 400 mg was administered due to progressive respiratory worseningSevere COVID-19 patients with hyper-inflammatory features admitted outside ICU requiring NIV and/or high-flow supplemental O~2~Safety, efficacyCapra REur J Intern Med 2020Retrospective observational studyItaly8570 (control)63 (tocilizumab)Hydroxychloroquine, lopinavir/ritonavirTocilizumab once within 4 daysCOVID-19-related pneumonia and respiratory failure, not needing mechanical ventilationSurvival rateColaneri M Microorganisms2020Retrospective case-control studyItaly11264 (control)62 (tocilizumab)Hydroxychloroquine, azithromycin, low weight heparin, methylprednisoloneFirst administration was 8 mg/kg (up to a maximum 800 mg per dose) intravenously, repeated after 12 hCritically ill patients with severe COVID-19 pneumoniaAdmission to the ICU and 7-day mortality rateGokhale Y EClinicalMedicine2020Retrospective cohort studyIndia16155 (control)52 (tocilizumab)Antibiotics, hydroxychloroquine oseltamivir, low molecular weight heparin, methylprednisoloneA single intravenous dose of 400 mgCOVID-19 with oxygen saturation of 94% or less despite giving supplemental oxygen of 15 L/min via non-rebreathing mask or PaO2/FiO2 ratio of less than 200DeathGuaraldi GLancet Rheumatol2020Retrospective observational cohort studyItaly54469 (control)64 (tocilizumab)Oxygen supply to target SaO~2~ reaching at least 90%, hydroxychloroquine, azithromycin at the physician's discretion when suspecting a bacterial respiratory super-infection, lopinavir--ritonavir or darunavir--cobicistat, low molecular weight heparinIntravenous tocilizumab was administered at 8 mg/kg bodyweight (up to a maximum of 800 mg) administered twice, 12 h apart; the subcutaneous formulation was used when there was a shortage of the intravenous formulation, at a dose of 162 mg administered in two simultaneous doses, one in each thighSevere pneumonia defined at least one of the following: presence of a respiratory rate of 30 or more breaths per minute, peripheral blood SaO~2~ of less than 93% in room air, a ratio of PaO~2~ to FiO~2~ of less than 300 mmHg in room air, and lung infiltrates of more than 50% within 24--48 h, according to Chinese management guidelines for COVID-19Death or invasive mechanical ventilationKlopfenstein T Med Mal Infect2020Retrospective case-control studyFrance4571 (control)77 (tocilizumab)Hydroxychloroquine or lopinavir-ritonavir, antibiotics, less commonly corticosteroids1 or 2 doses (no detail was reported)All critically COVID-19 patients in tocilizumab group, fewer critically ill patients in controlDeath and/or ICU admissionsMoreno-Pérez OJ Autoimmun2020Retrospective cohort studySpain23657 (control)62 (tocilizumab)No detail was reportedInitial 600 mg, with a second or third dose (400 mg) in case of persistent or progressive diseaseSevere COVID-19 pneumoniaAll-cause mortalityPotere NAnn Rheum Dis2020Retrospective case--control studyItaly8054 (control)56 (tocilizumab)Hydroxychloroquine, darunavir/cobicistat, lopinavir/ritonavir, systemic corticosteroid324 mg given as two concomitant subcutaneous injectionsSevere COVID-19 pneumonia with hypoxemia (oxygen saturation \< 90% on room air) requiring supplemental oxygen through nasal cannulas or maskRequirement of IMV or deathRojas-Marte GR QJM: An International Journal of Medicine 2020Retrospective, case--control, single-center studyUSA19362 (control)59 (tocilizumab)Hydroxychloroquine, azithromycin, corticosteroids anticoagulation, remdesivir, antibiotics for suspected bacterial infections, vasopressorsNo detail was reportedAdult patients hospitalized with severe COVID-19Overall mortality rateSomers ECClin Infect Dis2020Randomized controlled trialUSA15460 (control)55 (tocilizumab)Hydroxychloroquine, remdesivir, NSAIDs, ACEI/ARB, vasopressors, anticoagulation corticosteroidThe standard tocilizumab dose was 8 mg/kg (maximum 800 mg) × 1, additional doses were discouragedSevere COVID-19 patients requiring mechanical ventilationSurvival probability after intubationFig. 1Forest plot of pooled mortality of severely ill coronavirus disease 2019 (COVID-19) patients from included studies

Our meta-analysis had several limitations: (1) most included studies were retrospective analysis of cases, resulting in poor quality of the included studies; (2) the uniformity of the diagnostic criteria for severe COVID-19 needs to be improved, and the extraction of related factors is limited; and (3) extraction of the original data is incomplete, and some data cannot be converted due to the lack of relevant data.

In summary, this is the first meta-analysis demonstrating the efficacy of tocilizumab treatment in severely ill COVID-19 patients.
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